AEVIS VICTORIA SA (CH:AEVS)
:AEVS
Top Page
AEVIS VICTORIA SA
(AEVS)
Select Model
Select Model
Rating:43Neutral
Price Target:
CHF12.50
▼(-7.75% Downside)
Action:ReiteratedDate:04/07/26
The score is held down mainly by inconsistent profitability and high leverage despite revenue growth and improving operating cash flow. Technicals add downside pressure with weak momentum and price below major moving averages, while valuation offers limited support given the high P/E and no dividend yield provided.
Positive Factors
Revenue Growth
Sustained revenue growth from ~696.6M to ~1.13B over five years indicates durable demand and successful expansion of hospital and clinic services. This scale supports bargaining power with suppliers and insurers and provides a foundation for operational improvements and long-term service investment.
Negative Factors
High Leverage
Debt materially exceeds equity, raising refinancing and covenant risk and limiting strategic flexibility. High leverage increases sensitivity to interest costs and constrains the firm's ability to invest, pursue acquisitions, or absorb operational shocks without deleveraging or external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained revenue growth from ~696.6M to ~1.13B over five years indicates durable demand and successful expansion of hospital and clinic services. This scale supports bargaining power with suppliers and insurers and provides a foundation for operational improvements and long-term service investment.
Read all positive factors
AEVIS VICTORIA SA (AEVS) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF1.11B
Dividend YieldN/A
Average Volume (3M)11.01K
Price to Earnings (P/E)―
Beta (1Y)-0.13
Revenue Growth9.72%
EPS GrowthN/A
CountryCH
Employees4,731
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-0.05
Shares Outstanding84,529,460
10 Day Avg. Volume5,888
30 Day Avg. Volume11,014
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)2.21
Price to Sales (P/S)0.99
P/FCF Ratio230.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF17.00Price Target Upside25.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.19
Revenue Forecast (FY)CHF1.13B
AEVIS VICTORIA SA Business Overview & Revenue Model
Company Description
Aevis Victoria SA engages in healthcare, hospitality, lifestyle, and infrastructure sectors in Switzerland. The company operates through Hospitals, Hospitality, Telemedicine, and Real Estate segments. It operates 22 hospitals with 1,496 beds; mana...
How the Company Makes Money
AEVIS VICTORIA SA makes money primarily through operating revenues generated by its healthcare services subsidiaries (notably its private hospitals/clinics operations). Key revenue streams typically include payments for inpatient and outpatient tr...
AEVIS VICTORIA SA Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
38
Negative
Cash Flow
52
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.13B | 1.01B | 914.36M | 1.03B | 823.26M |
| Gross Profit | 193.03M | 789.90M | 170.09M | 185.41M | 137.56M |
| EBITDA | 24.91M | 92.49M | 49.06M | 128.29M | 83.47M |
| Net Income | -20.11M | -2.87M | -39.30M | 58.81M | -4.26M |
Balance Sheet | |||||
| Total Assets | 1.91B | 2.00B | 1.86B | 1.79B | 1.73B |
| Cash, Cash Equivalents and Short-Term Investments | 28.98M | 36.92M | 80.71M | 75.43M | 63.42M |
| Total Debt | 949.83M | 1.07B | 1.01B | 970.03M | 841.27M |
| Total Liabilities | 1.35B | 1.42B | 1.32B | 1.28B | 1.14B |
| Stockholders Equity | 509.75M | 530.85M | 491.89M | 469.34M | 485.92M |
Cash Flow | |||||
| Free Cash Flow | 4.87M | -18.80M | -66.06M | 40.28M | -24.07M |
| Operating Cash Flow | 72.56M | 46.50M | 42.67M | 114.30M | 33.53M |
| Investing Cash Flow | 56.05M | -62.28M | 35.56M | -56.82M | 21.63M |
| Financing Cash Flow | -136.51M | -28.06M | -72.95M | -45.46M | -57.31M |
AEVIS VICTORIA SA Technical Analysis
Negative
13.55
Price Trends
13.49
Negative
13.35
Negative
13.35
Negative
Market Momentum
-0.11
Positive
43.90
Neutral
52.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:AEVS, the sentiment is Negative. The current price of 13.55 is above the 20-day moving average (MA) of 13.41, above the 50-day MA of 13.49, and above the 200-day MA of 13.35, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 43.90 is Neutral, neither overbought nor oversold. The STOCH value of 52.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:AEVS.
AEVIS VICTORIA SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | CHF3.83B | 18.40 | ― | 4.14% | 2.66% | 2.91% | |
60 Neutral | CHF3.01B | 11.86 | ― | 4.46% | -4.68% | -5.79% | |
52 Neutral | CHF999.39M | 72.95 | ― | 0.77% | -3.45% | -49.82% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | CHF2.18B | 143.14 | ― | 0.68% | 27.24% | 122.39% | |
43 Neutral | CHF1.11B | -55.96 | ― | ― | 9.72% | ― |
* Healthcare Sector Average
CH:AEVS
AEVIS VICTORIA SA
13.15
0.25
1.94%
CH:ADEN
Adecco Group AG
17.99
-2.36
-11.60%
CH:DKSH
DKSH Holding AG
58.90
5.54
10.38%
CH:COTN
COMET Holding AG
280.00
75.90
37.19%
CH:XLS
Xlife Sciences Ltd.
21.50
2.10
10.82%
CH:SKAN
SKAN Group AG
44.45
-16.29
-26.82%
AEVIS VICTORIA SA Corporate Events
AEVIS VICTORIA Lifts Revenue and NAV but Books 2025 Loss as Growth Investments Mount
Apr 2, 2026
AEVIS VICTORIA SA reported a 14.3% rise in 2025 group revenue to CHF 1.21 billion and steady NAV growth, even as heavy growth investments and the absence of MA gains pushed the group to a CHF 25.6 million loss. Swiss Medical Network remained the m...
See-Spital Secures Bond Refinancing Through Long-Term Sale-and-Lease-Back Deal With Infracore
Mar 30, 2026
See-Spital has agreed to sell the building and land of its Horgen site to hospital real estate specialist Infracore SA and lease it back under a long-term rental agreement, securing refinancing for a CHF 100 million bond maturing in July 2026. The...
Swiss Medical Network boosts revenue, expands integrated care model and targets higher margins for 2026
Mar 27, 2026
Swiss Medical Network Holding SA reported a strong 2025 performance, with consolidated gross revenue rising 21.7% to CHF 988.5 million and EBITDA up 17% to CHF 45.6 million, while net debt fell by CHF 112.5 million, enhancing financial flexibility...
AEVIS VICTORIA’s Hospitality Arm Posts Solid 2025 Growth on Strong Demand and Premium Strategy
Mar 23, 2026
AEVIS VICTORIA’s hospitality division, operated through MRH Switzerland AG, delivered solid growth in 2025 driven by strong demand, premium positioning and ongoing operational improvements across its hotel portfolio in Switzerland and London...
Infracore posts strong 2025 results and boosts independent board majority
Mar 11, 2026
Infracore AG, the hospital real estate arm partly owned by AEVIS VICTORIA, reported solid 2025 results with rental income of CHF 66.1 million, total revenue including revaluation gains of CHF 82.5 million and EBITDA of CHF 76.7 million. The portfo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.